 CAMBRIDGE, Mass., March 22, 2021 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 2021 Annual Meeting on Womens Cancer, being held as a virtual meeting from March 19-25, 2021. 